Lyell Immunopharma (LYEL) Earnings Date & Reports

Key Takeaways

• Lyell Immunopharma is scheduled to report second quarter 2026 results around August 11–12, 2026, with the company yet to confirm the exact date.
• Consensus estimates point to an earnings per share (EPS) loss of approximately $2.03, compared to a loss of $2.89 per share in the same quarter last year.
• Revenue expectations remain minimal, with consensus estimates around $4,600 to $5,900, reflecting the company's pre-revenue, clinical-stage status.
• Cash burn and runway remain central investor concerns, with the company reporting a net loss of $24.2 million in the first quarter of 2026.
• Clinical pipeline updates will likely drive market reaction more than financial figures, particularly progress on the lead candidate ronde-cel and the LYL273 solid tumor program.
• Wall Street remains largely bullish, with a consensus "Moderate Buy" rating and an average price target near $38, though the stock has declined roughly 58% year-to-date.

Earnings Context and Why It Matters

Lyell Immunopharma's upcoming second quarter report lands at a critical juncture for the clinical-stage cell therapy company. With no approved products generating revenue, the focus has shifted squarely to execution across its late-stage pipeline, particularly the pivotal PiNACLE trial of rondecabtagene autoleucel (ronde-cel) in large B-cell lymphoma (LBCL). Stifel initiated coverage with a Buy rating and a $44 price target in late July, highlighting the company's registrational-stage positioning. However, shares have been under sustained pressure, trading near $13 after starting 2026 above $30. Investors are looking for concrete evidence that clinical timelines remain on track and that the company's cash position can fund operations through key data readouts expected in 2027.

Earnings Expectations

For the second quarter ended June 30, 2026, Wall Street analysts expect Lyell Immunopharma to report a net loss per share in the range of approximately $2.02 to $2.17, with consensus clustering around $2.03 according to TipRanks data. This would represent a meaningful improvement from the $2.89 per-share loss recorded in the year-ago quarter. Revenue is expected to be negligible—consensus estimates range from roughly $4,600 to $5,900—consistent with the company's pre-commercial stage.

In the prior quarter (Q1 2026), Lyell reported a net loss of $24.2 million, or $1.10 per share, which beat consensus estimates that had projected a loss of approximately $2.41 to $2.78 per share. The narrower loss was driven in part by a $17.6 million gain tied to a securities purchase agreement. Non-GAAP (Generally Accepted Accounting Principles, adjusted to exclude certain non-cash items) net loss for Q1 was $37.8 million. Historically, LYEL has beaten EPS estimates in six of the last eight quarters, though revenue has consistently remained near zero.

Given the company's pre-revenue profile, the headline numbers are unlikely to move the stock significantly. Instead, investors will parse the earnings release and conference call for updates on clinical enrollment progress, manufacturing performance metrics, and forward cash runway guidance.

AI Screener

For traders and investors looking to filter through thousands of stocks and ETFs with precision, Tickeron's AI Screener offers an AI-powered discovery tool that scans the market using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener leverages artificial intelligence to help identify trade ideas, breakout candidates, and trending stocks more efficiently than manual screening, making it a useful resource for those tracking earnings season movers or searching for opportunities in the biotechnology space. Explore the AI Screener to see how it can streamline your market research process.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 print is cautious but attentive. Lyell's stock has been under heavy selling pressure throughout 2026, falling from approximately $30.78 at the start of the year to around $12.80 in late July—a decline of roughly 58%. The stock's 52-week range spans from $9.28 to $45.00, underscoring the volatility typical of clinical-stage biotech names.

Following the Q1 2026 earnings release on May 6, the stock dipped approximately 3.8% the next day despite an EPS beat, suggesting that financial results alone carry limited weight for this name. The Q4 2025 report in March triggered a sharper 14% single-day selloff after the company posted a larger-than-expected loss. These reactions underscore a pattern: clinical and regulatory updates, rather than quarterly financials, are the primary drivers of LYEL's stock. Heading into Q2, the market is particularly attuned to any mention of the pivotal PiNACLE trial timeline, the planned Biologics License Application (BLA) submission in 2027, and updates from the LYL273 colorectal cancer program.

Forward Outlook and Key Factors to Monitor

Looking beyond the second quarter print, several developments will shape Lyell Immunopharma's trajectory through late 2026 and into 2027.

The most significant catalyst remains the PiNACLE pivotal trial of ronde-cel in third-line and later LBCL. The single-arm study, which is enrolling approximately 120 patients, uses overall response rate as its primary endpoint. Pivotal data are expected in mid-2027, with a BLA submission planned for the second half of that year. Any updates on enrollment pace or manufacturing success rates—which stood at 97% among 108 treated patients in earlier-stage data—will be closely monitored.

The PiNACLE-H2H Phase 3 head-to-head trial, which began dosing in early 2026 and compares ronde-cel directly against standard-of-care CD19 CAR T-cell therapies in the second-line setting, represents another key value driver. Progress here could differentiate Lyell from competitors in the increasingly crowded cell therapy landscape.

In solid tumors, the LYL273 program targeting metastatic colorectal cancer continues Phase 1 dose escalation, with preliminary data showing a median progression-free survival of 7.8 months at dose level 2. Management has indicated it plans to engage the FDA (Food and Drug Administration) by year-end 2026 to discuss a pivotal trial design, with the aim of launching that study in the first half of 2027.

On the financial side, investors should monitor the company's cash burn rate and any commentary around funding needs. Lyell ended Q1 2026 with a strong current ratio of over 7.0 and more cash than debt on its balance sheet, but pre-commercial biotechs burn through capital quickly. The ability to fund operations through key data readouts without dilutive financing will be a central theme on the earnings call.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.